Who would argue that we don’t need innovation in biopharmaceuticals? Some are even calling for disruptive innovation, to tackle the thorny issues of affordability and availability of new medical products.
Others are screaming “that’s impossible, never going to happen”.
It may surprise you to know it could be possible, and the work of the late, sadly departed Clayton M. Christenson, provides the clue. Christenson used the work of Henry Ford, at the Ford Motor Company, as an example of what is, and what isn’t, disruptive innovation. He and his team pointed out that initially, the automobile itself was not disruptive; it was an expensive luxury item, not able to challenge the incumbent horse-drawn vehicles used for transportation.
When Ford came along with his mass-produced product, however, it was only then that the seeds of disruption were sown, and the rest is history.
At PharmaFlow, we believe the world of development and supply of medical products is the horse-drawn carriage. We are introducing it to the Model-T Ford.
This example of disruptive innovation above is covered in the opening chapter of TAMING THE BIG PHARMA MONSTER by Speaking Truth to Power, written by managing consultant at PharmaFlow Hedley Rees.
We hope this has piqued your curiosity and appetite to learn more about disruptive innovation in biopharmaceuticals – check it out here.